Copies of any marketing authorizations for Epkinly (epcoritamab) from any other drug A final mock-up of the Package Insert (if applicable), in
by K Izutsu 2024 Cited by 5Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Epkinly [Package Insert]. Genmab K.K.; 2024. 19. Campo E, Swerdlow
Epkinly [package insert] Plainsboro, NJ. Genmab; May 2024. 4. Tepkinly [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH
Epkinly 4 mg/0.8 mL single-dose vial: xx Epkinly 48 mg/0.8 mL single-dose vial: xx VII. References 1. Epkinly [package insert]. Plainsboro, NJ; Genmab US, Inc.; May 2024. Accessed February 2024. 2. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in
On J, The Food and Drug Administration approved epcoritamab-bysp (e.g, Epkinly) Epkinly [package insert]. Plainsboro, NJ; Genmab
EPKINLY demonstrated a remarkable 82% ORR with mDOR EPKINLY [package insert]. Plainsboro, NJ: Genmab US, Inc. and North Chicago, IL: AbbVie Inc. 2024. 2.
And the paperwork, sometimes called the medication guide or patient package insert, may contain details about interactions. If Epkinly doesn t come with paperwork, you can ask your pharmacist to
Epkinly should only be administered by a qualified health care professional with appropriate medical support to manage severe reactions such as CRS and ICANS. Package insert. Genmab and AbbVie
Drug Administration (FDA) approved drugs when the off-label use Epkinly [package insert]. Plainsboro, NJ: Genmab US, Inc.; May 2024
I would like to know more about this package. ^.^